Primary outcomes of the VIDI study: phase 2 double-masked randomized active-controlled study of ASP8232 for diabetic macular edema

摘要

BackgroundASP8232 is a potent and specific small molecule vascular adhesion protein-1 (VAP-1) inhibitor. This study evaluated the effect of ASP8232 on excess retinal thickness when given alone or in combination with ranibizumab in patients with center-involved diabetic macular edema (CI-DME).